从2017NCCN新版骨肿瘤指南看骨肉瘤、尤文肉瘤的诊治进展和未来方向
鲍其远
王际壮
温竣翔
沈宇辉
张伟滨
1.200025,上海交通大学医学院附属瑞金医院骨科2.200025,上海交通大学医学院附属瑞金医院骨科3.200025,上海交通大学医学院附属瑞金医院骨科4.200025,上海交通大学医学院附属瑞金医院骨科5.200025,上海交通大学医学院附属瑞金医院骨科
摘要：National Comprehensive Cancer Network ( NCCN ) of the united states has updated its 2nd version of 2017 guideline on the clinical management of bone cancer. Some minor revisions have been updated in terms of the radiological examination and the Ewing sarcoma terminology, and a major revision regarding the change of 'considering second line chemotherapy ( 2B )' to 'maintain original chemotherapy or consider second line chemotherapy ( 2B )', while no remarkable renewals were seen in the remaining content of NCCN bone cancer guideline. Given the effortless endeavor toward the clinical and basic research, the prognosis of primary high-grade bone malignancy has reached a plateau in the past three decades. In this article, we aim to discuss, together with recent evidence, the updated NCCN bone cancer guideline from chemotherapy, molecular biomarker, target agents, metastatic heterogeneity and metastasectomy, and suggest our future directions for the treatment of osteosarcoma and Ewing sarcoma.
关键词：骨肿瘤骨肉瘤肉瘤
分类号：R738.1(运动系肿瘤)
资助基金：上海市科学技术委员会科技创新行动计划临床医学领域(17411951900)上海市卫生和计划生育委员会面上课题(201740139)上海交通大学医学院高峰学科-临床医学"研究型医师"项目(20152204)
论文发表日期：2018-01-01
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：3( 1-3 )
英文信息